Buprenorphine: Difference between revisions

(Switch SMW query from broadtable to table format for better layout with TOC)
(Reduce excessive bold: 32->9 instances; keep only critical safety warnings)
 
Line 8: Line 8:
*ED-initiated buprenorphine '''increases 30-day treatment engagement ~5-fold''' compared to referral alone (D'Onofrio 2015 RCT)<ref name="DOnofrio2015">D'Onofrio G, O'Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636-1644.</ref>
*ED-initiated buprenorphine '''increases 30-day treatment engagement ~5-fold''' compared to referral alone (D'Onofrio 2015 RCT)<ref name="DOnofrio2015">D'Onofrio G, O'Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636-1644.</ref>
*Combined with [[Special:MyLanguage/naloxone|naloxone]] in most sublingual/buccal formulations (Suboxone) to deter IV misuse — naloxone has no clinical effect when taken sublingually as intended
*Combined with [[Special:MyLanguage/naloxone|naloxone]] in most sublingual/buccal formulations (Suboxone) to deter IV misuse — naloxone has no clinical effect when taken sublingually as intended
*'''No special waiver or certification is required''' to prescribe buprenorphine — the X-waiver (DATA 2000) was permanently eliminated by the Consolidated Appropriations Act of 2023<ref name="CAA2023">Consolidated Appropriations Act, 2023, Pub. L. No. 117-328, § 1262, 136 Stat. 4459 (2022).</ref>
*No special waiver or certification is required to prescribe buprenorphine — the X-waiver (DATA 2000) was permanently eliminated by the Consolidated Appropriations Act of 2023<ref name="CAA2023">Consolidated Appropriations Act, 2023, Pub. L. No. 117-328, § 1262, 136 Stat. 4459 (2022).</ref>


==Administration==
==Administration==
Line 14: Line 14:
*Type: [[Special:MyLanguage/Opioid|Opioid]] — partial mu-agonist; used for OUD maintenance/induction and chronic pain
*Type: [[Special:MyLanguage/Opioid|Opioid]] — partial mu-agonist; used for OUD maintenance/induction and chronic pain
*Dosage Forms:
*Dosage Forms:
**Sublingual tablet: buprenorphine/naloxone 2 mg/0.5 mg, 4 mg/1 mg (generic), '''8 mg/2 mg, 12 mg/3 mg'''; buprenorphine monoproduct 2 mg, 8 mg
**Sublingual tablet: buprenorphine/naloxone 2 mg/0.5 mg, 4 mg/1 mg (generic), 8 mg/2 mg, 12 mg/3 mg; buprenorphine monoproduct 2 mg, 8 mg
**Sublingual/buccal film: buprenorphine/naloxone 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, 12 mg/3 mg (Suboxone); buprenorphine buccal film 75, 150, 300, 450, 600, 750, 900 mcg (Belbuca — for pain)
**Sublingual/buccal film: buprenorphine/naloxone 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, 12 mg/3 mg (Suboxone); buprenorphine buccal film 75, 150, 300, 450, 600, 750, 900 mcg (Belbuca — for pain)
**Extended-release subcutaneous injection: Sublocade 100 mg, 300 mg (monthly); Brixadi 8, 16, 24, 32 mg (weekly) and 64, 96, 128 mg (monthly)
**Extended-release subcutaneous injection: Sublocade 100 mg, 300 mg (monthly); Brixadi 8, 16, 24, 32 mg (weekly) and 64, 96, 128 mg (monthly)
Line 35: Line 35:


*For patients in moderate-severe withdrawal, especially those using fentanyl/high-potency synthetic opioids
*For patients in moderate-severe withdrawal, especially those using fentanyl/high-potency synthetic opioids
*'''Day 1:''' Buprenorphine/naloxone 8 mg SL; may repeat '''8 mg in 1-2 hours (total up to 16-32 mg on day 1)
*Day 1: Buprenorphine/naloxone 8 mg SL; may repeat 8 mg in 1-2 hours (total up to 16-32 mg on day 1)
*Buprenorphine has been shown to be safe at doses up to 32-64 mg''' without respiratory depression<ref name="Hughes2024"/>
*Buprenorphine has been shown to be safe at doses up to 32-64 mg without respiratory depression<ref name="Hughes2024"/>
*If precipitated withdrawal occurs with the initial dose, '''give more buprenorphine''' (not less) to saturate remaining unoccupied receptors<ref name="Hughes2024"/>
*If precipitated withdrawal occurs with the initial dose, give more buprenorphine (not less) to saturate remaining unoccupied receptors<ref name="Hughes2024"/>
*'''Discharge dose:''' 16 mg/day (or the total daily dose that stabilized the patient in the ED), prescribed as buprenorphine/naloxone with outpatient follow-up
*Discharge dose: 16 mg/day (or the total daily dose that stabilized the patient in the ED), prescribed as buprenorphine/naloxone with outpatient follow-up


====Low-Dose ("Micro") Induction====
====Low-Dose ("Micro") Induction====


*For patients '''not yet in withdrawal''' or who cannot tolerate withdrawal (e.g., patients on full-agonist opioids, patients using fentanyl who cannot wait for COWS ≥8)
*For patients not yet in withdrawal or who cannot tolerate withdrawal (e.g., patients on full-agonist opioids, patients using fentanyl who cannot wait for COWS ≥8)
*Start with very low doses of buprenorphine (e.g., 0.5-1 mg SL) and gradually increase over 3-7 days while the full agonist is slowly tapered
*Start with very low doses of buprenorphine (e.g., 0.5-1 mg SL) and gradually increase over 3-7 days while the full agonist is slowly tapered
*Avoids precipitated withdrawal by allowing gradual receptor binding
*Avoids precipitated withdrawal by allowing gradual receptor binding
Line 50: Line 50:


*Occurs when buprenorphine is given while a full agonist is still occupying mu receptors (more common with fentanyl due to lipophilicity and depot effect)
*Occurs when buprenorphine is given while a full agonist is still occupying mu receptors (more common with fentanyl due to lipophilicity and depot effect)
*'''Treat with more buprenorphine''' — increasing the dose is first-line to overcome competition for receptor binding<ref name="Hughes2024"/>
*Treat with more buprenorphine — increasing the dose is first-line to overcome competition for receptor binding<ref name="Hughes2024"/>
*Adjunctive symptom management:
*Adjunctive symptom management:
**[[Special:MyLanguage/Ondansetron|Ondansetron]] for nausea/vomiting
**[[Special:MyLanguage/Ondansetron|Ondansetron]] for nausea/vomiting
Line 66: Line 66:
==Pediatric Dosing==
==Pediatric Dosing==


*'''OUD:''' Generally managed by addiction medicine/pediatric specialists; weight-based dosing for adolescents ≥16 years follows adult guidelines
*OUD: Generally managed by addiction medicine/pediatric specialists; weight-based dosing for adolescents ≥16 years follows adult guidelines
*'''Acute pain (parenteral):''' 2-12 years: 2-6 mcg/kg q4-6h PRN
*Acute pain (parenteral): 2-12 years: 2-6 mcg/kg q4-6h PRN


==Special Populations==
==Special Populations==
Line 73: Line 73:
===Pregnancy===
===Pregnancy===


*Buprenorphine is '''recommended''' in pregnancy for OUD — associated with reduced neonatal abstinence syndrome (NAS) severity and shorter NICU stays compared to methadone<ref name="JONES2010">Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320-2331.</ref>
*Buprenorphine is recommended in pregnancy for OUD — associated with reduced neonatal abstinence syndrome (NAS) severity and shorter NICU stays compared to methadone<ref name="JONES2010">Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320-2331.</ref>
*Use '''buprenorphine monoproduct''' (without naloxone) in pregnancy — although buprenorphine/naloxone is increasingly accepted and may be used if the monoproduct is unavailable<ref name="ACOG2017">ACOG Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. Obstet Gynecol. 2017;130(2):e81-e94.</ref>
*Use buprenorphine monoproduct (without naloxone) in pregnancy — although buprenorphine/naloxone is increasingly accepted and may be used if the monoproduct is unavailable<ref name="ACOG2017">ACOG Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. Obstet Gynecol. 2017;130(2):e81-e94.</ref>
*'''Do NOT stop buprenorphine in pregnancy''' — withdrawal poses greater risk to fetus than continued treatment
*'''Do NOT stop buprenorphine in pregnancy''' — withdrawal poses greater risk to fetus than continued treatment


===Lactation===
===Lactation===


*Buprenorphine is '''considered compatible with breastfeeding''' — minimal transfer to breast milk, low oral bioavailability in the infant<ref name="ACOG2017"/>
*Buprenorphine is considered compatible with breastfeeding — minimal transfer to breast milk, low oral bioavailability in the infant<ref name="ACOG2017"/>
*Benefits of breastfeeding generally outweigh risks in stable patients on buprenorphine maintenance
*Benefits of breastfeeding generally outweigh risks in stable patients on buprenorphine maintenance
*Monitor infant for sedation and adequate weight gain
*Monitor infant for sedation and adequate weight gain
Line 92: Line 92:
*'''Avoid or do not use''' in severe hepatic impairment
*'''Avoid or do not use''' in severe hepatic impairment
*Extended-release formulations (Sublocade, Brixadi) are '''contraindicated in moderate-severe hepatic impairment''' (cannot rapidly adjust dose once injected)
*Extended-release formulations (Sublocade, Brixadi) are '''contraindicated in moderate-severe hepatic impairment''' (cannot rapidly adjust dose once injected)
*Obtain LFTs if clinical concern, but '''LFTs are not required before initiating buprenorphine in the ED'''<ref name="Hughes2024"/>
*Obtain LFTs if clinical concern, but LFTs are not required before initiating buprenorphine in the ED<ref name="Hughes2024"/>


==Contraindications==
==Contraindications==
Line 104: Line 104:


*'''[[Special:MyLanguage/Benzodiazepines|Benzodiazepines]] and other CNS depressants:''' Additive respiratory depression risk, but '''this is NOT a contraindication to buprenorphine initiation''' — the risk of death from untreated OUD exceeds the risk of co-prescribing<ref name="ASAM2023"/>
*'''[[Special:MyLanguage/Benzodiazepines|Benzodiazepines]] and other CNS depressants:''' Additive respiratory depression risk, but '''this is NOT a contraindication to buprenorphine initiation''' — the risk of death from untreated OUD exceeds the risk of co-prescribing<ref name="ASAM2023"/>
*'''CYP3A4 inhibitors''' (ketoconazole, ritonavir, erythromycin): May increase buprenorphine levels — monitor for sedation
*CYP3A4 inhibitors (ketoconazole, ritonavir, erythromycin): May increase buprenorphine levels — monitor for sedation
*'''CYP3A4 inducers''' (rifampin, carbamazepine, phenytoin): May decrease buprenorphine levels — may require dose increase
*CYP3A4 inducers (rifampin, carbamazepine, phenytoin): May decrease buprenorphine levels — may require dose increase
*'''Full mu-agonist opioids:''' Buprenorphine may precipitate withdrawal if given while full agonist is occupying receptors; full agonists may have diminished effect in patients on buprenorphine maintenance
*Full mu-agonist opioids: Buprenorphine may precipitate withdrawal if given while full agonist is occupying receptors; full agonists may have diminished effect in patients on buprenorphine maintenance
*'''[[Special:MyLanguage/Naloxone|Naloxone]]:''' Higher doses of naloxone (standard overdose doses) may precipitate withdrawal in buprenorphine-dependent patients, though buprenorphine's high receptor affinity makes it relatively naloxone-resistant
*[[Special:MyLanguage/Naloxone|Naloxone]]: Higher doses of naloxone (standard overdose doses) may precipitate withdrawal in buprenorphine-dependent patients, though buprenorphine's high receptor affinity makes it relatively naloxone-resistant


==Adverse Reactions==
==Adverse Reactions==
Line 143: Line 143:
==Mechanism of Action==
==Mechanism of Action==


*'''Partial mu-opioid receptor agonist:''' Produces submaximal activation — provides analgesia and prevents withdrawal but with limited euphoria and a ceiling effect on respiratory depression
*Partial mu-opioid receptor agonist: Produces submaximal activation — provides analgesia and prevents withdrawal but with limited euphoria and a ceiling effect on respiratory depression
*'''Kappa-opioid receptor antagonist:''' May contribute to antidepressant and anti-dysphoric effects
*Kappa-opioid receptor antagonist: May contribute to antidepressant and anti-dysphoric effects
*'''Very high receptor binding affinity:''' Displaces full agonists from mu receptors (causes precipitated withdrawal if administered too early) and blocks effects of subsequently administered full agonists
*Very high receptor binding affinity: Displaces full agonists from mu receptors (causes precipitated withdrawal if administered too early) and blocks effects of subsequently administered full agonists


==Comments==
==Comments==


*'''ED-initiated buprenorphine is the standard of care''' — supported by ACEP policy statement, ASAM guidelines, and landmark RCT data showing reduced opioid use, increased treatment engagement, and reduced mortality<ref name="DOnofrio2015"/><ref name="Armour2025">Armour R, et al. Initiation of buprenorphine in the emergency department or emergency out-of-hospital setting: A mixed-methods systematic review. Am J Emerg Med. 2025;88:12-22.</ref>
*'''ED-initiated buprenorphine is the standard of care''' — supported by ACEP policy statement, ASAM guidelines, and landmark RCT data showing reduced opioid use, increased treatment engagement, and reduced mortality<ref name="DOnofrio2015"/><ref name="Armour2025">Armour R, et al. Initiation of buprenorphine in the emergency department or emergency out-of-hospital setting: A mixed-methods systematic review. Am J Emerg Med. 2025;88:12-22.</ref>
*'''Prescribe a bridge supply at discharge:''' At minimum, prescribe enough buprenorphine/naloxone to last until the outpatient follow-up appointment (typically 7-14 day supply). A common discharge dose is 16 mg/day<ref name="Hughes2024"/>
*Prescribe a bridge supply at discharge: At minimum, prescribe enough buprenorphine/naloxone to last until the outpatient follow-up appointment (typically 7-14 day supply). A common discharge dose is 16 mg/day<ref name="Hughes2024"/>
*Buprenorphine and buprenorphine/naloxone are clinically interchangeable. Buprenorphine/naloxone is now '''generic''' in the US
*Buprenorphine and buprenorphine/naloxone are clinically interchangeable. Buprenorphine/naloxone is now generic in the US
*Patients presenting on extended-release buprenorphine (Sublocade, Brixadi) who have breakthrough withdrawal may need supplemental sublingual buprenorphine — consult with the patient's prescriber
*Patients presenting on extended-release buprenorphine (Sublocade, Brixadi) who have breakthrough withdrawal may need supplemental sublingual buprenorphine — consult with the patient's prescriber
*For patients with OUD in the ED who decline buprenorphine, still treat withdrawal symptoms, provide harm reduction resources ([[Special:MyLanguage/naloxone|naloxone kit]], fentanyl test strips), and offer a prescription or referral for a future visit
*For patients with OUD in the ED who decline buprenorphine, still treat withdrawal symptoms, provide harm reduction resources ([[Special:MyLanguage/naloxone|naloxone kit]], fentanyl test strips), and offer a prescription or referral for a future visit

Latest revision as of 08:47, 22 March 2026


Background

  • Partial mu-opioid agonist and kappa-opioid antagonist used for opioid use disorder and chronic pain
  • Has a ceiling effect for respiratory depression — at higher doses, respiratory depression plateaus, making it significantly safer than full agonists in overdose[1]
  • ED-initiated buprenorphine increases 30-day treatment engagement ~5-fold compared to referral alone (D'Onofrio 2015 RCT)[2]
  • Combined with naloxone in most sublingual/buccal formulations (Suboxone) to deter IV misuse — naloxone has no clinical effect when taken sublingually as intended
  • No special waiver or certification is required to prescribe buprenorphine — the X-waiver (DATA 2000) was permanently eliminated by the Consolidated Appropriations Act of 2023[3]

Administration

  • Type: Opioid — partial mu-agonist; used for OUD maintenance/induction and chronic pain
  • Dosage Forms:
    • Sublingual tablet: buprenorphine/naloxone 2 mg/0.5 mg, 4 mg/1 mg (generic), 8 mg/2 mg, 12 mg/3 mg; buprenorphine monoproduct 2 mg, 8 mg
    • Sublingual/buccal film: buprenorphine/naloxone 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, 12 mg/3 mg (Suboxone); buprenorphine buccal film 75, 150, 300, 450, 600, 750, 900 mcg (Belbuca — for pain)
    • Extended-release subcutaneous injection: Sublocade 100 mg, 300 mg (monthly); Brixadi 8, 16, 24, 32 mg (weekly) and 64, 96, 128 mg (monthly)
    • Transdermal patch: 5, 7.5, 10, 15, 20 mcg/hr (Butrans — for pain)
    • Injectable solution: 0.3 mg/mL (Buprenex — for acute pain, available IV/IM)
  • Routes of Administration: sublingual, buccal, subcutaneous, transdermal, IV, IM
  • Common Trade Names: Suboxone (buprenorphine/naloxone), Subutex (buprenorphine mono), Sublocade (extended-release monthly), Brixadi (extended-release weekly/monthly), Belbuca (buccal film for pain), Butrans (transdermal patch for pain), Buprenex (injectable)

Adult Dosing

ED-Initiated Buprenorphine

There are three induction strategies. Choice depends on withdrawal status and clinical scenario.[4][1]

Traditional Induction (patient in moderate-severe withdrawal, COWS ≥8-12)

  • For Clinical Opioid Withdrawal Scale (COWS) ≥8: give 4 to 8mg of Buprenorphine, observe 30 to 45min
    • Redose if COWS remains ≥8. Then discharge home with 16 mg a day to bridge until follow-up (an X-waiver is no longer required to prescribe buprenorphine).
  • For Clinical Opioid Withdrawal Scale (COWS) 0-7: Consider observing the patient until their COWS score is >8 for the standard buprenorphine induction.
    • Alternatively, you can prescribe consider unobserved home induction instructions available on paper [5][6] and app[7] [8].
  • If sublingual tablets/films unavailable then intravenous/intramuscular formulation (dose 0.3-0.9 mg every 6-12 hours) has been used for opioid withdrawal in the ED[9] and hospitalized[10] patients.
NIH National Institute on Drug Abuse ED Buprenorphine algorithm[11]

High-Dose ("Macro") Induction

  • For patients in moderate-severe withdrawal, especially those using fentanyl/high-potency synthetic opioids
  • Day 1: Buprenorphine/naloxone 8 mg SL; may repeat 8 mg in 1-2 hours (total up to 16-32 mg on day 1)
  • Buprenorphine has been shown to be safe at doses up to 32-64 mg without respiratory depression[1]
  • If precipitated withdrawal occurs with the initial dose, give more buprenorphine (not less) to saturate remaining unoccupied receptors[1]
  • Discharge dose: 16 mg/day (or the total daily dose that stabilized the patient in the ED), prescribed as buprenorphine/naloxone with outpatient follow-up

Low-Dose ("Micro") Induction

  • For patients not yet in withdrawal or who cannot tolerate withdrawal (e.g., patients on full-agonist opioids, patients using fentanyl who cannot wait for COWS ≥8)
  • Start with very low doses of buprenorphine (e.g., 0.5-1 mg SL) and gradually increase over 3-7 days while the full agonist is slowly tapered
  • Avoids precipitated withdrawal by allowing gradual receptor binding
  • Typically not completed in a single ED visit — requires either observation unit admission or close outpatient follow-up[4]

Precipitated Withdrawal Management

  • Occurs when buprenorphine is given while a full agonist is still occupying mu receptors (more common with fentanyl due to lipophilicity and depot effect)
  • Treat with more buprenorphine — increasing the dose is first-line to overcome competition for receptor binding[1]
  • Adjunctive symptom management:

Acute Pain (non-OUD)

  • IV/IM: 0.3 mg q6-8h PRN (parenteral formulation)
  • Transdermal (Butrans): 5-20 mcg/hr patch, changed weekly
  • Buccal film (Belbuca): Starting dose 75 mcg q12h, titrate as needed

Pediatric Dosing

  • OUD: Generally managed by addiction medicine/pediatric specialists; weight-based dosing for adolescents ≥16 years follows adult guidelines
  • Acute pain (parenteral): 2-12 years: 2-6 mcg/kg q4-6h PRN

Special Populations

Pregnancy

  • Buprenorphine is recommended in pregnancy for OUD — associated with reduced neonatal abstinence syndrome (NAS) severity and shorter NICU stays compared to methadone[12]
  • Use buprenorphine monoproduct (without naloxone) in pregnancy — although buprenorphine/naloxone is increasingly accepted and may be used if the monoproduct is unavailable[13]
  • Do NOT stop buprenorphine in pregnancy — withdrawal poses greater risk to fetus than continued treatment

Lactation

  • Buprenorphine is considered compatible with breastfeeding — minimal transfer to breast milk, low oral bioavailability in the infant[13]
  • Benefits of breastfeeding generally outweigh risks in stable patients on buprenorphine maintenance
  • Monitor infant for sedation and adequate weight gain

Renal Dosing

  • No dose adjustment required (primarily hepatically metabolized)[1]

Hepatic Dosing

  • Use with caution in moderate hepatic impairment; reduce dose
  • Avoid or do not use in severe hepatic impairment
  • Extended-release formulations (Sublocade, Brixadi) are contraindicated in moderate-severe hepatic impairment (cannot rapidly adjust dose once injected)
  • Obtain LFTs if clinical concern, but LFTs are not required before initiating buprenorphine in the ED[1]

Contraindications

  • Allergy to buprenorphine or naloxone
  • Severe respiratory depression (current; note: ceiling effect makes this very rare with buprenorphine alone)
  • Severe hepatic impairment (for extended-release formulations)
  • Not contraindicated in patients on benzodiazepines — co-prescribing carries risk but withholding buprenorphine carries greater mortality risk from untreated OUD[4]

Drug Interactions

  • Benzodiazepines and other CNS depressants: Additive respiratory depression risk, but this is NOT a contraindication to buprenorphine initiation — the risk of death from untreated OUD exceeds the risk of co-prescribing[4]
  • CYP3A4 inhibitors (ketoconazole, ritonavir, erythromycin): May increase buprenorphine levels — monitor for sedation
  • CYP3A4 inducers (rifampin, carbamazepine, phenytoin): May decrease buprenorphine levels — may require dose increase
  • Full mu-agonist opioids: Buprenorphine may precipitate withdrawal if given while full agonist is occupying receptors; full agonists may have diminished effect in patients on buprenorphine maintenance
  • Naloxone: Higher doses of naloxone (standard overdose doses) may precipitate withdrawal in buprenorphine-dependent patients, though buprenorphine's high receptor affinity makes it relatively naloxone-resistant

Adverse Reactions

Serious

  • Respiratory depression (rare due to ceiling effect; risk increased with concurrent CNS depressants or IV misuse)
  • Precipitated opioid withdrawal (if given before full agonist has cleared)
  • Hepatotoxicity (elevated transaminases; more common with pre-existing hepatic disease or hepatitis)
  • QT prolongation (mild; less clinically significant than with methadone)
  • Adrenal insufficiency (rare, with chronic use)
  • Neonatal withdrawal syndrome (in infants born to mothers on buprenorphine)
  • Anaphylaxis/angioedema (rare)

Common

  • Constipation
  • Nausea, vomiting
  • Headache
  • Insomnia
  • Diaphoresis
  • Peripheral edema
  • Dizziness, somnolence
  • Oral hypoesthesia (sublingual/buccal formulations)
  • Injection site reactions (extended-release formulations)

Pharmacology

  • Half-life: 24-42 hours (sublingual); 43-60 days (Sublocade depot)
  • Metabolism: Hepatic via CYP3A4 to active metabolite norbuprenorphine; also undergoes glucuronidation
  • Excretion: Primarily fecal (~70%); renal (~30% as metabolites)
  • Protein binding: ~96%
  • Ceiling effect for respiratory depression occurs at approximately 16-32 mg sublingual[1]

Mechanism of Action

  • Partial mu-opioid receptor agonist: Produces submaximal activation — provides analgesia and prevents withdrawal but with limited euphoria and a ceiling effect on respiratory depression
  • Kappa-opioid receptor antagonist: May contribute to antidepressant and anti-dysphoric effects
  • Very high receptor binding affinity: Displaces full agonists from mu receptors (causes precipitated withdrawal if administered too early) and blocks effects of subsequently administered full agonists

Comments

  • ED-initiated buprenorphine is the standard of care — supported by ACEP policy statement, ASAM guidelines, and landmark RCT data showing reduced opioid use, increased treatment engagement, and reduced mortality[2][14]
  • Prescribe a bridge supply at discharge: At minimum, prescribe enough buprenorphine/naloxone to last until the outpatient follow-up appointment (typically 7-14 day supply). A common discharge dose is 16 mg/day[1]
  • Buprenorphine and buprenorphine/naloxone are clinically interchangeable. Buprenorphine/naloxone is now generic in the US
  • Patients presenting on extended-release buprenorphine (Sublocade, Brixadi) who have breakthrough withdrawal may need supplemental sublingual buprenorphine — consult with the patient's prescriber
  • For patients with OUD in the ED who decline buprenorphine, still treat withdrawal symptoms, provide harm reduction resources (naloxone kit, fentanyl test strips), and offer a prescription or referral for a future visit


Indications by Condition

The following table is automatically generated from disease/condition pages across WikEM.

IndicationDoseContextRoutePopulation
Neonatal abstinence syndrome5mcg/kg q8hr initially (max 20mcg/kg q8hr)Alternative to morphine; may reduce hospital staySublingualPediatric
Opioid toxicity4 mg SL initial; may give additional 4 mg SL after 1-2 hours (total 8-16 mg on day 1)ED-initiated buprenorphine for OUDSLAdult

See Also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Hughes T, Nasser N, Mitra A. Overview of best practices for buprenorphine initiation in the emergency department. Int J Emerg Med. 2024;17:23. doi:10.1186/s12245-024-00593-6
  2. ↑ 2.0 2.1 D'Onofrio G, O'Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636-1644.
  3. ↑ Consolidated Appropriations Act, 2023, Pub. L. No. 117-328, § 1262, 136 Stat. 4459 (2022).
  4. ↑ 4.0 4.1 4.2 4.3 Weimer MB, Herring AA, Kawasaki SS, Meyer M, Kleykamp BA, Ramsey KS. ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids. J Addict Med. 2023;17(6):632-639. doi:10.1097/ADM.0000000000001202
  5. ↑ A Guide for Patients Beginning Buprenorphine Treatment at Home https://medicine.yale.edu/edbup/quickstart/Home_Buprenorphine_Initiation_338574_42801_v1.pdf
  6. ↑ A Patient’s Guide to Starting Buprenorphine at Home from ASAM https://www.asam.org/docs/default-source/education-docs/unobserved-home-induction-patient-guide.pdf
  7. ↑ Buprenorphine Home Induction Apple App Store https://apps.apple.com/us/app/buprenorphine-home-induction/id1449302173
  8. ↑ Starting Buprenorphine from Google Play Store https://play.google.com/store/apps/details?id=com.amstonstudio.bup&hl=en_US&gl=US
  9. ↑ Berg ML, et. al. Evaluation of the use of buprenorphine for opioid withdrawal in an emergency department. Drug Alcohol Depend. 2007 Jan 12;86(2-3):239-44. https://doi.org/10.1016/j.drugalcdep.2006.06.014. Epub 2006 Aug 22. PMID: 16930865.
  10. ↑ Welsh CJ, Suman M, Cohen A, et al. The use of intravenous buprenorphine for the treatment of opioid withdrawal in medically ill hospitalized patients. Am J Addict. 2002;11(2):135-40 https://doi.org/10.1080/105500490290087901
  11. ↑ https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/algorithm.pdf
  12. ↑ Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320-2331.
  13. ↑ 13.0 13.1 ACOG Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. Obstet Gynecol. 2017;130(2):e81-e94.
  14. ↑ Armour R, et al. Initiation of buprenorphine in the emergency department or emergency out-of-hospital setting: A mixed-methods systematic review. Am J Emerg Med. 2025;88:12-22.
Retrieved from "https://www.wikem.org/w/index.php?title=Buprenorphine&oldid=388960"